… improvement in progression-free survival among patients with … The BRAF inhibitor vemurafenib
(Zelboraf, Genentech) was … improved progression-free survival and overall survival, as …

… compared with placebo, vemurafenib, and cobimetinib in … in overall survival can be achieved
with long-term treatment with this triplet combination versus vemurafenib plus cobimetinib. …

… We report the protocol-specified overall survival analysis of a double-blind, multicentre, …
safety of cobimetinib and vemurafenib compared with placebo and vemurafenib in previously …

… progression-free survival was significantly increased with vemurafenib plus cobimetinib
compared with vemurafenib … Overall survival data in the CoBRIM trial were immature at time of …

… of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib,
was reported previously. Here we present the prespecified interim overall survival analysis. …

… for overall survival across patient subgroups. C, Overall survival in cobimetinib plus
vemurafenib–… D, Cobimetinib plus vemurafenib–treated patients who achieved complete response …

… The first approved BRAFi was vemurafenib. The BRIM 3 randomized phase III study … that
vemurafenib (V) improved progression-free survival (PFS), overall survival (OS), and overall …

… We defined progression-free survival as the interval between treatment start date and date
of progression or death from any cause, whichever came first; we categorised progression …

9006 Background: Primary analysis of coBRIM showed significant improvement in PFS and
overall response rate (ORR) in BRAF V600 mutation–positive patients (pts) with advanced …

… V improved progression-free (PFS) and overall survival (OS) compared with placebo (P)+V
in pts with BRAF V600 -mutated advanced melanoma. We report updated survival outcomes …